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Abstract
Background
The use of cardiac implantable electronic devices (CIED) has risen steadily, yet the rate of
cardiac device infections (CDI) has disproportionately increased. Amongst all cardiac device
infections, the pocket infection is the most challenging diagnosis. Therefore, we aimed to
improve diagnosis of such pocket infection by identifying relevant biomarkers.
Methods
We enrolled 25 consecutive patients with invasively and microbiologically confirmed pocket
infection. None of the patients had any confounding conditions. Pre-operative levels of 14
biomarkers were compared in infected and control (n = 50) patients. Our selected biomark-
ers included white blood cell count (WBC), C-reactive protein (CRP), procalcitonin (PCT),
lipopolysaccharide binding protein, high-sensitivity C-reactive protein (HS-CRP), polymor-
phonuclear-elastase, presepsin, various interleukins, tumor necrosis factor α (TNF-α), and
granulocyte macrophage colony-stimulating factor (GM-CSF).
Results
Of the 25 patients with isolated pocket infection (70±13years, 76% male, 40% ICDs), none
presented with leukocytosis. In contrast, they had higher serum levels of HS-CRP (p = 0.019)
and PCT (p = 0.010) than control patients. Median PCT-level was 0.06 ng/mL (IQR 0.03–0.07
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ng/mL) in the study group versus 0.03 ng/mL (IQR 0.02–0.04 ng/mL) in controls. An optimized
PCT cut-off value of 0.05 ng/mL suggests pocket infection with a sensitivity of 60% and speci-
ficity of 82%. In addition TNF-α- and GM-CSF-levels were lower in the study group. Other bio-
markers did not differ between groups.
Conclusion
Diagnosis of isolated pocket infections requires clinical awareness, physical examination,
evaluation of blood cultures and echocardiography assessment. Nevertheless, measure-
ment of PCT- and HS-CRP-levels can aid diagnosis. However, no conclusion can be drawn
from normal WBC-values.
Clinical trial registration
clinicaltrials.gov identifier: NCT01619267
Introduction
Implantable pacemakers (PM) and cardioverter defibrillators (ICD) are standard treatment for
bradyarrhythmias, to ameliorate heart failure, and to protect against sudden cardiac death [1].
Worldwide implantation rates of cardiac implantable electronic devices (CIED) are estimated
at 1,250,000 pacemakers and 410,000 cardioverter defibrillators per year, with an annual
increase of roughly 5% [2–4]. The recent increase in device utilisation was driven by the needs
of an aging population coupled with an expansion of CIED functions and also their indications
[5–9]. Nevertheless, increased device use has also increased the incidence of complications.
Moreover, these infections have increased disproportionately versus the rate of implantation
[2, 10, 11]. This trend in cardiac device infection (CDI) burden is also attributed to the aging
population together with an increased prevalence of co-morbidities in current device recipi-
ents [2, 5]. The typical estimated annual infection rate is between 1% and 2%; although pub-
lished rates range from 0.5% to 8% [2, 12–19]. CDI are, not surprisingly, associated with
increased costs, significant morbidity, and higher mortality [13, 20–23].
CDI can be classified into three main types; [1] isolated pocket infection, [2] bloodstream
infection, or [3] cardiac device related infective endocarditis (CDRIE). Isolated pocket infection
is the most frequent, accounting for more than half of CDI [24, 25]. Early diagnosis and subse-
quent complete device and lead removal, combined with antibiotic treatment, are important to
avoid progression to sepsis or endocarditis [5, 16, 26, 27]. However, diagnosing a pocket infec-
tion can be challenging because many patients present with few or very mild symptoms or even
without any obvious signs of local infection [24, 28–30].
Such frequent lack of clear-cut symptoms of infection place the onus on clinical judgment
[28]. Conventional inflammation-related biomarkers, such as white blood count or erythro-
cyte sedimentation rate, are known to exhibit low sensitivity to cardiac device pocket infec-
tions. Hence, they rarely influence diagnostic decisions [24, 31–32]. Therefore, we aimed to
evaluate additional inflammatory biomarkers to determine if they enhance diagnosis of cardiac
device pocket infection.
Methods
The DIRT (Device associated infections–role of new diagnostic tools) study is a prospective,
multicentre, case-control evaluation of inflammatory biomarkers in a cohort of CIED
Biomarkers in isolated pocket infections
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recipients with and without pocket infections. Patients were recruited from five centres in Ger-
many, Croatia, and Italy. From August 2011 to October 2012, consecutive patients with sus-
pected cardiac device pocket infections and control patients at the time of pulse generator
exchange or lead revision were invited to participate in the study. The study was approved by
the ethical review board of the Technische Universita¨t Mu¨nchen, Munich, and conducted
according to the principles of the Declaration of Helsinki. The study was registered at clinical-
trials.gov (identifier, NCT01619267). All patients provided written informed consent and 50
mL of peripheral blood were drawn for biomarker analysis.
Inclusion and exclusion criteria
The inclusion criterion for the evaluation of inflammatory biomarkers was the presence of a
cardiac device pocket infection (as described below). Controls were recruited from patients
presenting for a pulse generator exchange or lead revision (unrelated to infections) at the same
centres during the same period.
Exclusion criteria (for both groups) were the presence of a bloodstream infection or an
infective endocarditis; attributed according to modified Duke criteria [33, 34]. Patients were
excluded if they presented with current antibiotic treatment, or other concomitant infectious,
or inflammatory disease. Additional exclusion criteria were circumstances that could influence
inflammatory biomarker levels; e.g. recent trauma, surgery, or burns, patients with active or
recent (within two years) malignancy, patients receiving systemic steroid therapy, and patients
on high-flux renal dialysis. Minors or adults under guardianship were excluded.
Diagnostic assessment
Fifty-three patients with cardiac device infection were screened and classified (Fig 1). All
patients underwent a baseline assessment, which included; the medical history, the indication
for device therapy and device related procedures, physical examination, and basic laboratory
tests including white blood count and C-reactive protein (CRP). In all patients with suspected
CDI, at least three sets of blood cultures, prior to initiation of antibiotic therapy, were drawn
in order to assess potential blood stream infection or infective endocarditis. Additionally, in all
these patients, transthoracic and transoesophageal echocardiography was performed to detect
valvular vegetation or newly developed valvular insufficiency (Fig 2).
An isolated generator pocket infection was assumed (in the absence of a bloodstream infec-
tion or infective endocarditis) if at least three out of the following seven local signs of inflam-
mation or infection were present: erythema, pain, warmth, swelling, induration, tenderness, or
fluctuation. Furthermore, hardware protrusion through the skin or pus discharge at the pocket
site (either spontaneous or expressed upon palpation of the site) was considered conclusive
evidence of pocket infection. In all patients with suspected pocket infection, the diagnosis was
required to be confirmed by surgical exploration of the generator pocket site showing purulent
or inflammatory changes. In cases of invasively confirmed CDI, we removed all hardware
using a transvenous lead extraction approach. In all patients with confirmed CDI, cultures
from the device pocket and from the leads were taken for microbiological analysis. If explora-
tion of the pocket failed to reveal a CDI, or if it had not been performed, the patient was ineli-
gible for the study.
After this assessment, patients were classified to have either an infection limited to the gen-
erator pocket–representing the target population–or to have an infection with systemic com-
ponents (i.e., bloodstream infection or definite and possible infectious endocarditis according
to the modified Duke criteria) and therefore excluded. [12, 33–34]
Biomarkers in isolated pocket infections
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Biomarker selection and analysis
In addition to basic laboratory tests of white blood count (WBC) and serum C-reactive protein
(CRP), we assessed 12 other biomarkers that could potentially support the diagnosis of cardiac
device pocket infection: procalcitonin (PCT), high-sensitivity CRP (HS-CRP), lipopolysaccha-
ride binding protein (LBP), presepsin, polymorphonuclear-elastase (PMN-E), interleukins
(IL)-1ß, -6, -8, -10, -23, tumor necrosis factor α (TNFα), and granulocyte macrophage colony-
stimulating factor (GM-CSF). The biomarker selection was primarily based on a systematic lit-
erature review, searching PubMed with terms related to cardiac device infections and bacterial
endocarditis. The query resulted in the identification of 10 biomarkers as promising candidates
to detect infection: WBC, CRP, HS-CRP, PCT, LBP, IL-1β, IL-6, IL8, TNF-α and PMN-Elastase
(Fig 3) [35–48]. Given the leading causative agents for device infection (bacteria in 80–90% of
cases; predominantly coagulase negative staphylococci and staphylococci aureus in 60–70% of
cases), and taking into account the inflammatory nature of the process and the specific inflam-
matory cascades involved, we solicited expert opinion; basic science researchers in immunology
or infectious disease and laboratory medicine specialists for their advice on the selection of addi-
tional biomarkers for the detection of chronic bacterial infections. Presepsin, IL-10. IL-23 and
GM-CSF were the markers suggested by these experts as worthy of evaluation (subsequently sub-
stantiated by literature review; Fig 3) [49–52]. The aim of testing numerous biomarkers was to
cover all inflammatory process cascades and to identify candidates for subsequent follow-up in a
larger study.
Fig 1. Study flow chart.
doi:10.1371/journal.pone.0172384.g001
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After informed consent, and prior to any antibiotic treatment or any invasive procedures,
50 mL of blood were drawn from study participants. The blood samples were divided between
heparin, EDTA, citrate, and plasma tubes–according to the assay method–centrifuged, and
stored at -70˚C. Analysis of biomarker concentrations was performed in a core-lab at the Ger-
man Heart Centre Munich using commercially available assays (Table 1). All analyses were
performed according to the manufacturers´ instructions.
Endpoint
The study endpoint was to assess the accuracy of 14 biomarkers in diagnosis of cardiac device
infection limited to the generator pocket.
Statistics
The DIRT study was designed as an explorative evaluation of the diagnostic accuracy of bio-
markers associated with cardiac device pocket infections. For this, patients were prospectively
and consecutively included until the target population—patients with isolated pocket infection
naïve to antibiotic pre-treatment—reached 25 and the control group reached 50. Because there
Fig 2. General diagnostic work up and identification of patients with an isolated pocket infection.
doi:10.1371/journal.pone.0172384.g002
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was no current data to indicate the potential efficacy of these biomarkers, our study was
intended as a preliminary evaluation and hence no pre-investigation power-analysis was per-
formed. Nevertheless, our predefined sample sizes were considered large enough to provide
sufficient discrimination.
Categorical data are presented as absolute and relative frequencies, continuous data as
mean ± standard deviation or as median with interquartile range (IQR). Comparisons were
performed using either chi-square or Fisher exact tests for categorical variables as appropriate.
Continuous variables were analysed using a two-sample t-test if normally distributed. Other-
wise, the Mann Whitney U-test was used. Initially, for inflammatory biomarkers with estab-
lished cut-off values, the diagnostic accuracy for isolated pocket infection was described by
values of sensitivity and specificity. Subsequently, receiver operating characteristic (ROC)
curves were drawn for all biomarkers. The area under the ROC curve (AUC) with 95% confi-
dence intervals was then calculated. Finally, the optimal cut-off value of each biomarker (i.e.,
the maximized sum of sensitivity and specificity; Youden index) was derived. Statistical analy-
ses were performed using SPSS V.21.0 (IBM Corporation, Armonk, USA).
Results
Study samples
According to the modified Duke criteria, cardiac device related infective endocarditis (CDRIE)
was diagnosed in five patients, bloodstream infection was confirmed in three, and pocket infection
Fig 3. Selection and description of the 14 analysed biomarkers.
doi:10.1371/journal.pone.0172384.g003
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was suspected in 45. After application of the inclusion and exclusion criteria, we analyzed blood
samples from 25 patients with invasively confirmed pocket infections (Fig 1).
Baseline characteristics
Demographic and baseline characteristics are summarized in Table 2. Generally, these did not
differ between groups. However, there was weak evidence to suggest that infected patients
were more likely to have ischemic cardiomyopathy and to have undergone more CIED proce-
dures more recently. Swab- or lead-cultures were available in 24 out of 25 of patients and were
positive in 20 out of 24 (83%) individuals. Pathogens in patients with isolated pocket infection
without antibiotic pretreatment included: Staphylococcus epidermidis (n = 12, 50%), Staphy-
lococcus capitis (n = 4, 17%), Staphylococcus aureus (n = 2, 8%), Staphylococcus haemolyticus
Table 1. Detailed overview of applied assays for biomarker-analysis.
Parameter Abbreviation Test-
Principle*
Assay Assay manufacturer Analyser Analyser manufacturer
White blood cell count WBC FFC Sysmex reagents Sysmex, Kobe, Japan XE-5000 Sysmex, Kobe, Japan
C-reactive protein CRP TIA CRP Gen.3 Roche Diagnostics,
Mannheim, Germany
cobas c501 Roche Diagnostics,
Mannheim, Germany
Procalcitonin PCT ECLIA Elecsys BRAHMS
PCT
BRAHMS, Berlin,
Germany
cobas e411 Roche Diagnostics,
Mannheim, Germany
Lipopolysaccharide binding
protein
LBP CLIA LBP Siemens, Erlangen,
Germany
Immulite 1000 Siemens, Erlangen,
Germany
High-SensitivityC-reactive
protein
HS-CRP CLEIA Pathfast HS-CRP
CLEIA
Progen Biotechnik
GmbH, Heidelberg,
Germany
Pathfast
immunoanalyser
Mitsubishi Chemical
Europe, Du¨sseldorf,
Germany
Polymorphonuclear-elastase PMN-E ELISA PMN Elastase
(human) ELISA
DRG Instruments
GmbH, Marburg,
Germany
BEP 2000 Siemens, Erlangen,
Germany
Presepsin Presepsin CLEIA Pathfast Presepsin
CLEIA
Progen Biotechnik
GmbH, Heidelberg,
Germany
Pathfast
immunoanalyser
Mitsubishi Chemical
Europe, Du¨sseldorf,
Germany
Interleukin 1β IL-1β CBA BD CBA
inflammatory
cytokine kit
BD Biosciences
Pharmingen, San
Diego, USA
FACS Calibur BD Biosciences,
Heidelberg, Germany
Interleukin 6 IL-6 CBA BD CBA
inflammatory
cytokine kit
BD Biosciences
Pharmingen, San
Diego, USA
FACS Calibur BD Biosciences,
Heidelberg, Germany
Interleukin 8 IL-8 CBA BD CBA
inflammatory
cytokine kit
BD Biosciences
Pharmingen, San
Diego, USA
FACS Calibur BD Biosciences,
Heidelberg, Germany
Interleukin 10 IL-10 CBA BD CBA
inflammatory
cytokine kit
BD Biosciences
Pharmingen, San
Diego, USA
FACS Calibur BD Biosciences,
Heidelberg, Germany
Interleukin 23 IL-23 ELISA Interleukin-23
(human) ELISA
DRG Instruments
GmbH, Marburg,
Germany
BEP 2000 Siemens, Erlangen,
Germany
Tumor necrosis factor α TNF-α CBA BD CBA
inflammatory
cytokine kit
BD Biosciences
Pharmingen, San
Diego, USA
FACS Calibur BD Biosciences,
Heidelberg, Germany
Granulocyte macrophage
colony-stimulating factor
GM-CSF ELISA GM-CSF (human)
ELISA
DRG Instruments
GmbH, Marburg,
Germany
BEP 2000 Siemens, Erlangen,
Germany
* FFC fluorescent flow cytometry, TIA turbidimetric immuno assay, ECLIA electrochemiluminescence immunoassay, CLIA chemiluminescent
immunometric assay CLEIA chemiluminescence enzyme immunoassay, ELISA enzyme-linked immunosorbent assay, CBA cytometric bead array
doi:10.1371/journal.pone.0172384.t001
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(n = 1, 4%), Pseudomonas aeruginosa (n = 1, 4%); no specific pathogen was identified in 4
(17%) patients.
Biomarker evaluation using established cut-offs
None of the routinely used laboratory biomarkers (WBC, CRP, HS-CRP, and PCT) were asso-
ciated with the presence of pocket infection when established reference values were used.
Notably, none of the participants presented with leukocytosis and the serum procalcitonin
(PCT)-level never exceeded the upper reference limit of 0.5 ng/mL used in the diagnosis of
Table 2. Characteristics of 25 patients with isolated cardiac device pocket infection and 50 control patients.
Characteristic Study group Control group p-value
Number, N 25 50 -
Age [yrs]* 69.8 ± 12.7 69.7 ± 12.6 0.98 ‡
Gender, male, N (%) 19 (76%) 33 (66%) 0.38 §
EF, [%]]* 47 ± 13 43 ± 17 0.45 ||
Device, ICD, N (%) 10 (40%) 27 (54%) 0.25 §
Creatinine, [mg/dl]]* 1.2 ± 0.6 1.1 ± 0.4 0.48 ||
Diabetes mellitus, N (%) 5 (20%) 10 (20%) 1.00 §
Ischemic cardiomyopathy, N (%) 14 (56%) 18 (36%) 0.10 §
Number of CIED-procedures † 1.0 0.8 0.11 ||
Months since first CIED-implantation 75 130 0.06 ||
* mean ± SD
† exclusive first CIED-implantation
‡ = T-Test
§ = Chi-Quadrat-Test
|| = Mann-Whitney U-Test
EF = ejection fraction; ICD = implantable cardioverter defibrillator; CIED = cardiac implantable electronic devices
doi:10.1371/journal.pone.0172384.t002
Table 3. Comparison of biomarker levels between infected and control groups using established cut-offs.
Study group Control group
Biomarker Unit Reference value exceeding reference value N exceeding reference value N P-value* Sensitivity Specifcity
WBC *109/l <10.0 0 / 25 0 / 50 - 0% 100%
CRP mg/l < 5.0 8 / 25 7 / 50 0.12 32% 86%
PCT ng/ml < 0.5 0 / 25 0 / 50 - 0% 100%
LBP μg/ml < 8.4 6 / 25 16 / 50 0.59 24% 68%
HS-CRP mg/l < 3.35 11 / 25 10 / 50 0.05 44% 80%
PMN-Elastase ng/ml <35.0 20 / 25 33 / 50 0.29 80% 34%
Presepsin pg/ml <365 19 / 25 24 / 50 0.03 76% 52%
IL-1β pg/ml < 8.0 0 / 25 0 / 50 - 0% 100%
IL-6 pg/ml < 7.25 4 / 25 4 / 50 0.43 16% 92%
IL-8 pg/ml <15.0 7 / 25 16 / 50 0.80 28% 68%
IL-10 pg/ml < 8.0 2 / 25 4 / 50 1.00 8% 92%
IL-23 pg/ml <15.0 19 / 25 32 / 50 0.43 76% 36%
TNF-α pg/ml < 6.0 1 / 25 2 / 50 1.00 4% 96%
GM-CSF pg/ml < 0.12 7 / 25 31 / 50 0.01 28% 38%
* Fisher´s exact test.
doi:10.1371/journal.pone.0172384.t003
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endocarditis or sepsis. CRP and HS-CRP levels were more often elevated in the study group
versus the controls. The difference was more pronounced for HS-CRP; however, the evidence
was weak.
In contrast, the less frequently used biomarkers provided stronger evidence of inter-group
differences. Presepsin levels above the established cut-off were more prevalent in patients with
pocket infections than in healthy controls; the sensitivity and specificity for pocket infection
diagnosis was moderate. GM-CSF was found to be significantly more frequently elevated
above the reference value in controls than in patients with pocket infections, however, sensitiv-
ity and specificity was low. Table 3 provides the details for each of the investigated biomarkers.
Biomarker evaluation using absolute concentrations
For each biomarker, the median concentrations and their IQRs and the AUC for each ROC
are shown in Fig 4. White blood counts did not differ between groups. However, infected
patients had statistically significantly higher serum levels of C-reactive protein (CRP, 2.7mg/L
vs. 1.6mg/L, 95% CI 0.53 to 0.79, p = 0.028), high-sensitivity CRP (HS-CRP, 3.1mg/L vs.
1.7mg/L, 95% CI 0.53 to 0.90, p = 0.019), and procalcitonin (PCT, 0.06ng/mL vs. 0.03ng/mL,
95% CI 0.55 to 0.82, p = 0.01) than controls. In contrast, GM-CSF- (0.12pg/mL vs. 0.59pg/mL,
95% CI 0.56 to 0.81, p = 0.01) and TNF-α-levels (0pg/mL vs. 1.1pg/mL, 95% CI 0.77 to 0.97,
p<0.01) were lower in infected patients versus controls. The concentrations of presepsin, LBP,
PMN-Elastase, and the tested interleukins (IL-1β, IL-6, IL-8, IL-10, IL-23) did not differ
between groups. The five biomarkers (CRP, HS-CRP, PCT, TNF-α and GM-CSF) with the
largest apparent potential to differentiate pocket infections are illustrated in Fig 5 as ROC
curves.
In addition, optimized cut-off values with maximized sensitivity and specificity were obtained
from ROC analysis applying the Youden Index. For the biomarkers established in routine diag-
nostics (CRP, HS-CRP, PCT), the optimized cut-offs resulted in moderate diagnostic power to
discriminate between patients with isolated cardiac device pocket infections and healthy con-
trols. Of these, PCT yielded the best combination of sensitivity and specificity. The optimized
PCT threshold of 0.05 ng/mL, which is above the 95th percentile of that found in a healthy popu-
lation, but 10-times lower than the established cut-off for septic conditions, achieved a sensitivity
of 60% and specificity of 82% (Table 4). Two of the additional biomarkers tested (TNF-α and
Fig 4. Comparison of biomarker levels between infected and control groups using absolute concentration.
doi:10.1371/journal.pone.0172384.g004
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GM-CSF), yielded comparable, or somewhat higher, sensitivity and specificity levels with opti-
mized cut-offs. For both markers, low serum concentrations were associated with the presence
of infection (Table 4).
Discussion
Diagnosis of pocket infections for implanted cardiac devices is challenging and requires con-
siderable experience [35, 48]. Experience is needed first to initiate necessary treatment early
enough to avoid development of sepsis or endocarditis. Second, experience is required to
avoid unnecessary pocket exploration, with its associated risks, in uninfected patients even
when the pocket appears suspicious. Given this spectrum of necessary to unnecessary interven-
tion, biomarkers could aid diagnosis and thereby assist the decision-making process.
Fig 5. Receiver operator characteristic curve (ROC)-Analysis for the relevant biomarkers.
doi:10.1371/journal.pone.0172384.g005
Table 4. Comparison of sensitivity and specificity for relevant biomarkers applying established or optimized cut-off values.
Biomarker Unit established cut-off value Sensitivity Specificity optimized cut-off value Sensitivity Specificity
CRP mg/l >5.0 32% 86% >2.1 64% 62%
HS-CRP mg/l >3.35 44% 80% >3.0 56% 76%
PCT ng/ml >0.5 0% 100% >0.05 60% 82%
GM-CSF pg/ml >0.12 28% 36% >0.24 72% 62%
TNF-α pg/ml >6.0 4% 96% >0.22 92% 84%
doi:10.1371/journal.pone.0172384.t004
Biomarkers in isolated pocket infections
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In the DIRT study, we provide the first ever assessment of the ability of biomarkers associ-
ated with inflammatory processes to differentiate between patients with and without cardiac
device pocket infections. Data on such differentiation is scarce and limited to measurement of
WBC- and CRP-levels. However, in the majority of patients with cardiac device pocket infec-
tion, WBC and CRP levels are normal and therefore provide minimal diagnostic value [24,
32]. These prior observations are confirmed in our study and further underline the unsuitabil-
ity of non-elevated WBC- and CRP-levels to rule out CDI.
The DIRT study was not restricted to these standard infection parameters, but also assessed
12 additional biomarkers. The group of chosen biomarkers are not specific for the germs caus-
ing pocket infections. However, because they cover the different cascades of the inflammatory
processes, they represent promising candidates to detect isolated pocket infections. (Fig 3) We
used biomarkers with proven responsiveness to bacteria because of the predominately bacterial
character of CIED-infection. However, we also included a broad set of interleukins (involved
in the specific and unspecific cascade) in order to detect other independent inflammatory pro-
cesses. This concept of detection of inflammatory reactions is also the same as that underlying
the recommended use of F-FDG-PET/CT or SPECT/CT in suspected endocarditis.
When we applied standard cut-offs, increased serum levels of presepsin, and decreased lev-
els GM-CSF, were associated with cardiac device pocket infections. However, the respective
sensitivity and specificity provided was, at best, moderate. The finding of increased presepsin
serum levels in patients with cardiac device pocket infections appears intuitively reasonable;
but, we cannot explain why GM-CSF expression was attenuated.
When we compared the absolute concentration of the biomarkers, we found some evidence
of associations for CRP, HS-CRP, PCT, TNF-α and GM-CSF. Increased levels of CRP,
HS-CRP and PCT were associated with infections, as were decreased values of TNF-α and
GM-CSF. We subsequently used these associations to derive optimized cut-off values and
thereby improve the sensitivity and specificity of the tests. However, some of these markers
may fail to provide effective and valid screening. For example, CRP concentrations are com-
monly used to support diagnosis of infective endocarditis and to monitor patient response to
therapy [36]. The concentrations tend to be highest in acute S. aureus infections [37], a patho-
gen also frequently found in cardiac device pocket infections. Application of the optimized ref-
erence value to 2.1 mg/L instead of standard 5.0 mg/L increased sensitivity and specificity to
64% and 62%, respectively. However, CRP is not specific for bacterial infections and can also
be elevated in viral infections and after surgery or trauma. We excluded these conditions and
so evaluation in a less selected patient population could be expected to diminish the apparent
differentiating ability. Therefore, CRP does not appear an ideal parameter to detect infection.
Similar arguments may also apply to HS-CRP [38]. Furthermore, in terms of sensitivity and
specificity, HS-CRP did not provide any additional advantage over the use of CRP.
In contrast, procalcitonin (PCT) serum levels in suspected cardiac device pocket infection
may differentiate between healthy and infected patients. Using the optimized cut-off reference
value of 0.05 ng/mL (one tenth the standard cut-off value), sensitivity and specificity were 60%
and 82%, respectively. This device infection specific PCT cut-off value of>0.05ng/mL is above
the normal value in a healthy population. A study of 492 samples (performed with the Elecsys
BRAHMS PCT assay) revealed a normal value of 0.046 ng/mL (representing the 95th percen-
tile) [53]. Thus, patients with a PCT value of>0.05ng/mL have less than a 5% chance of a
false-positive result, i.e. being a healthy subject.
PCT is known to be an accurate marker for systemic bacterial infection (independent of the
pathogen) and, when compared to CRP, it is less prone to influence by viral infections, surgery,
or trauma [39]. PCT has also gained importance in the diagnosis and monitoring of infective
endocarditis; a differential diagnosis to isolated cardiac device pocket infection. Although PCT
Biomarkers in isolated pocket infections
PLOS ONE | DOI:10.1371/journal.pone.0172384 March 6, 2017 11 / 17
levels observed in infective endocarditis differ between assays and also vary according to the
duration of infection, they are usually higher than those observed in our cohort of infected
patients [35, 40–41]. In our experience, levels of PCT>0.5 ng/mL are typically associated with
systemic infection (bloodstream and infectious endocarditis). In order to stimulate future
research, we need to prove our pocket-infection-specific cut-off value prospectively. We also
need to establish an upper limit that would be suggestive of systemic or septic conditions.
Relatively low–but elevated–serum concentrations of PCT in cardiac device pocket infec-
tions may be explained by the localized nature of the infection. In strictly localized infection,
there is pronounced increase in PCT levels only if the infection involves surrounding tissues
or becomes systemic [42]. Thus, the use of a PCT assay with a low detection limit (in our study
0.02 ng/mL) may be required.
One potential disadvantage of using PCT serum concentration is its rapid decrease in suc-
cessfully treated patients [42, 43]. Therefore, ideally, blood samples should be drawn before the
initiation of antibiotic treatment (as was the case in our study).
The optimized cut-offs for infection diagnosis for GM-CSF and TNF-α produced higher
sensitivities and specificities versus CRP, HS-CRP, and PCT. Low serum concentrations of
GM-CSF and TNF-α correlated with pocket infection. This finding appears counter-intuitive
because, in general, increased expression of these regulators would be expected to occur as
part of the inflammatory response. However, these low levels could represent an expression of
the entity’s pathogenesis; i.e., a low expression may indicate a poor immune response which
thereby facilitates infection. We acknowledge that these explanations are speculative; however,
they are hypothesis-generating concepts to stimulate future research. In order to know if and
how a cytokine is deregulated in a certain condition, we need to compare normal physiological
values with those expressed in the pathology of interest. Curiously, prior studies failed to dem-
onstrate elevated TNF-α-levels in patients with systemic infective endocarditis [44, 45]. The
authors speculated that this occurred because of down-regulation of immune cells during per-
sistent stimulation or because of limited ability to stimulate specific cytokines [41].
Another crucial area of research for all relevant biomarkers is to identify the date of applica-
bility after index surgery. From studies analysing WBC count and (18)F-FDG uptake after
device implantation/revision, we know the post-operative inflammation process persists for
4–8 weeks after device implantation. For example, after device implantation (<60 days), 10–
15% of all patient exhibited a >50% increase in WBC count; a modest WBC count increase of
18 ± 30% was observed for the entire cohort [54]. In addition, Sarrazin et al. reported residual
post-operative inflammation present 4 to 8 weeks after surgery [55]. Moreover, the current
ESC guidelines on infectious endocarditis recommend a PET/CT scan for infective endocardi-
tis only if the implantation (prosthetic) took place at least three months earlier [56]. Therefore,
a conservative approach would be not to use such biomarkers until at least eight weeks after
implantation. However, the current use of PCT for stewardship of antibiotic therapy duration
in patients after surgery, or with community-acquired pneumonia, may provide a compelling
argument that PCT levels respond quickly to changes in inflammatory and infectious condi-
tions. [57, 58]. Also, an in vivo half-life of 22–25 hours provides a rationale for a shorter pro-
hibited period. Nevertheless, we currently lack strong evidence to support the reliability of any
biomarker immediately after surgery. However, most patients with suspected pocket infection
are admitted several months, rather than weeks, after surgery.
The diagnosis of isolated pocket infection will continue to require a critical clinical aware-
ness, careful patient history assessment, precise physical examination, and a basic workup (i.e.
blood cultures, transthoracic and transoesophageal echocardiography). Although one should
not draw conclusions from WBC-levels within the normal range, some laboratory parameters
(e.g. PCT, CRP, HS-CRP) may provide additional information in the diagnostic decision
Biomarkers in isolated pocket infections
PLOS ONE | DOI:10.1371/journal.pone.0172384 March 6, 2017 12 / 17
process. Assessment of PCT has become a routine laboratory parameter used in our evaluation
of patients with suspected CIED infection. In cases of possible pocket infection, when the
Duke Criteria are not met and local signs are unconvincing (less than three present), we assign
a PCT measurement above the cut-off value of 0.05 ng/mL a weight equal to that of a local
sign. However, this diagnostic strategy needs to be assessed in a prospective study.
Limitations
The present study was designed as a pilot evaluation to identify biomarkers worthy of investi-
gation in the diagnosis of cardiac device pocket infections. Therefore, the number of patients
included was small. Nonetheless, we assessed a wide variety of biomarkers. CRP, HS-CRP,
Procalcitonin, TNF-α, and GM-CSF provided the best discrimination of CDI. However, the
specific values used for detection of cardiac device-associated infections differed from standard
cut-offs. Our revision of these standard values should be assessed in a prospective study.
Patients with co-morbidities that might interfere with biomarker levels in CDI were
excluded. Therefore, our results may some limits to their generalizability. Specifically, our cut-
off values may not apply to patients on renal dialysis, patients with altered immune response
(e.g., patients on steroids), or after surgery/trauma, or those with concomitant malignant dis-
eases. Furthermore, patients with antibiotic pre-treatment were also excluded because this
could influence the results.
Conclusion
Diagnosis of cardiac device pocket infection remains primarily based on the judgment of expe-
rienced physicians. CRP, HS-CRP, and procalcitonin with specific cut-offs for cardiac device
infections may provide objective evidence to assist with diagnosis. In contrast, white blood
count, lipopolysaccharide binding protein, presepsin, polymorphonuclear-elastase, and inter-
leukins-1ß, -6, -8, -10, -23, do not appear to provide sufficient discrimination to aid diagnosis.
The role of depressed levels of tumor necrosis factor α and granulocyte macrophage colony-
stimulating factor in cardiac device pocket infections warrants further investigation.
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